193 related articles for article (PubMed ID: 26207804)
1. Precision Medicine: At What Price?
Ferkol T; Quinton P
Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804
[No Abstract] [Full Text] [Related]
2. Cystic fibrosis drug is not cost effective, says NICE.
Gulland A
BMJ; 2016 Jun; 353():i3409. PubMed ID: 27325384
[No Abstract] [Full Text] [Related]
3. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
[No Abstract] [Full Text] [Related]
4. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
[TBL] [Abstract][Full Text] [Related]
5. Genericisation in cost-effectiveness analysis of cystic fibrosis medicines.
Beattie A; Moore A; Ramagopalan SV
Lancet; 2024 Jun; 403(10444):2591-2592. PubMed ID: 38879249
[No Abstract] [Full Text] [Related]
6. Orkambi's Slick Unveiling Puts Insurers in a Bind.
Silverman E
Manag Care; 2015 Aug; 24(8):16-7. PubMed ID: 26399136
[No Abstract] [Full Text] [Related]
7. New cystic fibrosis drug paves the way for orphan diseases.
Cooney D
Lancet Respir Med; 2013 Apr; 1(2):104. PubMed ID: 24429084
[No Abstract] [Full Text] [Related]
8. [Causal therapy is available].
Meißner T
MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
[No Abstract] [Full Text] [Related]
9. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
10. Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi.
Hollis A
Healthc Policy; 2019 Aug; 15(1):70-80. PubMed ID: 31629457
[TBL] [Abstract][Full Text] [Related]
11. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
12. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
Kaiser J
Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
[No Abstract] [Full Text] [Related]
13. The effectiveness and value of novel treatments for cystic fibrosis.
Tice JA; Kuntz KM; Wherry K; Seidner M; Rind DM; Pearson SD
J Manag Care Spec Pharm; 2021 Feb; 27(2):276-280. PubMed ID: 33506736
[No Abstract] [Full Text] [Related]
14. Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France.
Olivereau L; Nave V; Garcia S; Perceval M; Rabilloud M; Durieu I; Reynaud Q
J Cyst Fibros; 2020 May; 19(3):402-406. PubMed ID: 31902692
[TBL] [Abstract][Full Text] [Related]
15. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
Jones AM; Barry PJ
Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
[No Abstract] [Full Text] [Related]
16. A combination therapy for cystic fibrosis.
Brodsky JL; Frizzell RA
Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
[TBL] [Abstract][Full Text] [Related]
17. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
Mayer M
Evid Based Med; 2016 Jun; 21(3):83-6. PubMed ID: 26718821
[No Abstract] [Full Text] [Related]
18. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
Heltshe SL; Cogen J; Ramos KJ; Goss CH
Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
[No Abstract] [Full Text] [Related]
19. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
Desch M
Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
[No Abstract] [Full Text] [Related]
20. CFTR modulators: transformative therapies for cystic fibrosis.
Dwight M; Marshall B
J Manag Care Spec Pharm; 2021 Feb; 27(2):281-284. PubMed ID: 33506726
[No Abstract] [Full Text] [Related]
[Next] [New Search]